Meta-iodobenzylguanidine conjugated to 131 I-iodine is an methods: (1) survival of clonogens derived from monolayer effective agent for the targeted radiotherapy of tumors of culture; (2) survival of clonogens derived from disaggreneural crest origin which express the noradrenaline transgated multicellular spheroids; and (3) 
Introduction
Meta-iodobenzylguanidine (MIBG) is an analogue of the adrenergic neurone blockers guanethidine and bretylium. 1 It is actively taken up by the noradrenaline transporter (NAT) 2 into cells of the adrenal medulla, adrenergic nerve cells and tumors such as phaechromocytoma and neuroblastoma which are derived from the neural crest. 3 Radioiodinated MIBG can be used for imaging 4, 5 as well as targeted radiotherapy. 6, 7 Early studies of patients with recurrent or refractory neuroblastoma treated with 131 I MIBG have been encouraging, 8 but it appears unlikely that 131 I MIBG used alone will be curative. MIBG is a small molecule which penetrates multicellular tumor spheroids and probably tumors more readily than antibodies. 9 An attractive feature of tumor targeting with 131 I MIBG is that cancer cells which fail to accumulate a lethal quantity of 131 I MIBG may still absorb ␤-radiation from neighboring, targeted cells. 10 Although 131 I MIBG is currently one of the best available agents for targeted radiotherapy, its use is confined to a few NAT-expressing tumor types which selectively accumulate the radiopharmaceutical. In order to determine whether 131 I MIBG could be used to treat diverse tumor types for which no specific, targetable characteristic currently exists, we have used a recombinant pREP9 plasmid to transfect the bovine NAT cDNA, 11 under the control of the RSV promoter/enhancer, into a human, glioblastoma cell line (UVW) which does not express the NAT gene. For this initial in vitro study, the pREP9 plasmid was employed. This is an Epstein-Barr virus (EBV)-based vector which contains an EBV origin of replication (oriP) and nuclear antigen (EBNA-1) allowing high-copy episomal replication and expression in primate cell lines. Transfectants exhibited a 15-fold enhancement of 131 I MIBG uptake and NAT-transfected clonogens succumbed to 131 I MIBG administration in a dose-dependent manner. The superior toxicity of 131 I MIBG to cells grown as spheroids rather than as monolayers confirmed the efficacy of the ␤-radiation cross-fire effect. These results demonstrate the potential of gene therapy-assisted, MIBG-targeted radiotherapy for the treatment of nonneuroectodermal tumors.
Results

MIBG uptake
To assess whether the bovine NAT cDNA was expressed and a functional protein produced in the transfected UVW cells, 131 I MIBG uptake was measured in UVW cells transfected with recombinant plasmids containing the bovine NAT cDNA (bNAT) in the sense and reverse orientation (pNAT+ and pNAT−, respectively). The cells transfected with the cDNA in the reverse orientation (UVW/pNAT−) were used throughout as a negative control to determine whether differences observed in the I MIBG uptake M Boyd et al 1148 UVW/pNAT+ cell line were due to the production of a functional NAT transporter protein rather than the pREP9 plasmid or the transfection procedure. UVW/pNAT+, UVW/pNAT− and nontransfected UVW cells (pNAT0) were seeded at 1 × 10 4 cells per well in sixwell plates and after 2 days the specific uptake of 131 I MIBG in each cell line was measured against desmethylimipramine (DMI) inhibited controls. DMI is a potent antagonist of noradrenaline transport. Optimal cell densities and methodologies for MIBG uptake studies were as previously determined. 
Cell kill
Having established a procedure for NAT gene expression which resulted in active 131 I MIBG uptake, we sought to evaluate the dose dependency of cell kill. These experiments were performed in cellular monolayers and also in a three-dimensional spheroid model. Figure  2a ). No clonogenic cell kill was observed in the nontransfected UVW cell line or in the UVW/pNAT− cell line, indicating that neither the pREP9 plasmid (lacking the bNAT insert in the correct orientation), nor the transfection procedure was toxic . However, in the UVW/pNAT+ cell line, which had substantial 131 I MIBG uptake capacity (Figure 1 ), a dose-dependent reduction in surviving fraction was observed (Figure 2a ). This demonstrated a clear 
MIBG in vitro. (a) Survival curves for UVW/PNAT0 (monolayer cells (untransfected), UVW/PNAT− cells (UVW cells transfected by NAT gene in reverse orientation) and UVW/PNAT+ cells (UVW cells transfected by NAT gene in sense orientation) ). The surviving fraction (SF) data are plotted as log mean values with error bars showing log standard deviations. The log scale (to base 10) is such that a value of −1 corresponds to a 10% surviving fraction. Only the PNAT+ cells showed a significant correlation with dose. (b) Survival curves for cells derived from disaggregated spheroids (UVW cells transfected with NAT gene in reverse or sense orientation; UVW/PNAT− and UVW PNAT+, respectively). The surviving fraction (SF) data are plotted as log mean values with error bars showing log standard deviations. The log scale is such that a value of −1 corresponds to a 10% surviving fraction. Only the UVW/PNAT+ cells showed a significant correlation with dose.
I MIBG uptake M Boyd et al correlation between 131 I MIBG uptake and cell kill in NAT-transfected UVW glioma cells.
Colony formation after
131
I MIBG exposure of multicellular spheroids: Tumor spheroids are cellular aggregates which are useful in vitro models of micrometastases. Their three-dimensional structure provides greater opportunity for radiation cross-fire than two-dimensional cellular monolayers. Spheroids were grown as described and after 5 days when they were approximately 250 m in diameter, aliquots were removed and incubated in universal containers with various concentrations of 131 I MIBG. To allow the absorption of ␤-decay energy by neighboring nontransfected cells, the following procedure was employed. Spheroids were left intact during the 2 h incubation with the radiopharmaceutical and during the washing procedure which removed free 131 I MIBG. The spheroids were then placed in fresh universal containers, equilibriated with 5% CO 2 and returned intact to a rotating mixer at 37°C to maintain the integrity of individual spheroids. After 24 h the spheroids were disaggregated by agitation after addition of trypsin and the cells from each universal container were seeded at 1 × 10 3 in triplicate into 60 mm Petri dishes. The cultures were incubated at 37°C for 14 days or until the formation of large discrete colonies was observed. The surviving colonies were then stained, counted and analyzed as described for cellular monolayers. A dose-dependent reduction in surviving fraction was observed for cells from disaggregated spheroids comprised of UVW/pNAT+ cells compared with UVW/pNAT− spheroids. The surviving fraction was almost half of that obtained for monolayers at the maximum dose of 131 I MIBG (Figure 2b ). Once again, no cell kill was observed in the UVW/pNAT− cell line. The difference between the UVW/pNAT+ monolayer and spheroid cell survival curves is consistent with a contribution of dosedependent radiation cross-fire to cell kill in this threedimensional culture.
Growth delay after 131
I MIBG exposure of multicellular spheroids: Spheroid response to cytotoxic treatment can also be evaluated by the end-point of growth delay. This provides an assay of cytoxic effect which is independent of colony formation. In these experiments, spheroids were initially grown in stirrer flasks to 250-300 m diameter. Groups of spheroids were exposed to a range of activities of 131 I MIBG for 2 h, then washed and transferred individually on to 24-well plates. Individual spheroid growth was measured using a microscope coupled to an image analysis system which allowed serial monitoring of spheroid volume and the construction of growth curves based on median volume for each group. Figure  3 shows log-linear plots of relative spheroid volume (normalized to median volume at time zero) as a function of time after treatment for (1) UVW/pNAT− and (2) UVW/pNAT+ spheroids. ForUVW/pNAT− (spheroids transfected with bNAT cDNA in the reverse orientation), the growth curves of all spheroid groups were similar, with no correlation between growth pattern and dose group (Figure 3a) . By contrast, Figure 3b shows that for UVW/pNAT+ spheroids (sense orientation of NAT cDNA) there was a distinct spread of growth curves: spheroids in the higher dose groups showed more delayed growth. This provides further evidence that plasmid-mediated transfer, employed COS-1 cells 12 and HeLa cells 13 as hosts. These achieved three-and nine-fold enhancement of MIBG uptake, respectively. In the present study, by introduction of the bovine NAT cDNA, 11 we increased the host cells' capacity for active accumulation of MIBG by at least a factor of 15 compared with transporter-inhibited controls. Although the experimental results reported here are preliminary, and clinical applications some way ahead, it is of interest to consider what might be the clinical potential of this novel approach. The 15-fold enhancement of MIBG uptake, reported here for NAT gene transfected tumor cells, if reproduced in a clinical setting, corresponds to a tumor uptake of radiolabeled MIBG of 0.021%/g injected activity (assuming 70 kg 'standard man' with only passive uptake of MIBG in normal tissues). This is within the range reported for MIBG uptake of neuroblastomas in the clinic, and is superior to the uptakes typically achieved with radiolabeled monoclonal antibodies, 14 although less than the uptake of radio-iodide (commonly about 0.1%/g) observed for thyroid carcinomas. 15 This suggests that MIBG uptake levels capable of being clinically useful have been achieved in these first experiments. It is possible that even greater concentration of MIBG could be achieved in vitro by manipulation of factors which enhance expression of the transgene, enhance stability of its mRNA or facilitate integration of the protein into the cell membrane.
Our procedures were designed to evaluate the enhancement of MIBG therapy by gene manipulation using a simple in vitro model. This incorporated a forced expression of the NAT gene by neomycin selection. While such a method of driving transgene expression is nonphysiological, it may none the less be possible to employ our recombinant plasmid vector for initial assessment of this therapeutic strategy using in vivo model systems. This is due to the fact that after the removal from cell cultures of the selection agent, the transfectants' capacity for active uptake of MIBG remained constant over a period of 6 weeks (results not shown).
The most popular gene manipulation strategy applied to experimental cancer treatment attempts to confer drug sensitivity on malignant host cells. 16 Because the gene transfer process is inefficient, a bystander effect (eg diffusion of cytotoxic drug) is an essential component of this approach. Here, we report the first evidence of the feasibility of combining gene transfection with radionuclide therapy using MIBG as the molecular vehicle. Other investigators have employed gene transfer methods to induce tumor cells to express elevated levels of surface antigens 17, 18 and receptors 19, 20 to enhance targeting by radiolabeled antibodies and peptides, respectively. An alternative approach could involve transfection of the sodium iodide symporter combined with administration of Na 13 I. 21 This symporter facilitates the accumulation of iodide by the thyroid gland 20-to 40-fold with respect to the iodide concentration in plasma. 22 A particular advantage of strategies which seek to achieve the concentration in tumor cells of radionuclides with long range emissions, is the presence of a radiological bystander effect. That is the bombardment of nontransfectants by radioactive decay particles emanating from neighboring, successfully transfected cells which have been induced to accumulate radiopharmaceutical actively. This type of collateral cell kill has previously been demonstrated using the tumor spheroid culture system. 10, 23 The three-dimensional spheroid model was employed in the current study to determine experimentally the effectiveness of cross-fire radiation.
131
I MIBG was almost twice as toxic to spheroids compared with monolayers, suggesting that a substantial contribution to efficacy in the former system was due to the radiological bystander effect. Spheroids composed of a range of proportions of transfectants to nontransfectants will constitute a useful model system for the assessment of different types of bystander effect and to determine the minimum proportion of cells required to be transfected in spheroids, to result in total spheroid cell kill. These studies, which have direct relevance to the eradication of micrometastatic disease, are currently underway.
A further advantage of the strategy of NAT gene transfer with administration of radiolabeled MIBG, is the scope for flexibility of design of the targeting agent. For example, an analogue of MIBG ( 211 At MABG) has been synthesized by replacing the ␤-emitting radionuclide 131 Iiodine with the ␣-emitting halogen 211 At-astatine. This compound has similar uptake specificity to MIBG but much greater radiobiological effectiveness of cell killing. 24 A promising application of these tactics to glioma therapy, for example, could include virally mediated transfer of the NAT gene, under the control of a tumourspecific promoter (such as the E2F-1 promoter At MABG to the experimental therapy of various tumor types. This may indicate whether MIBG could eventually be used to treat the 15% of neuroblastoma patients whose tumors fail to express the NAT. It may also be feasible to enhance MIBG uptake in neuroblastomas which actively accumulate MIBG, thereby improving the liklihood of cure. This application will require the control of transgene expression by a neuroblastomaspecific sequence such as the tyrosine hydroxylase promoter.
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Materials and methods
Plasmids
The bovine NAT cDNA inserted into the EcoRI site of the eukaryotic expression vector pSG-5 (Stratagene, Cambridge, UK), was kindly provided by Dr Michael Bruss and Professor Heinz Bonisch (University of Bonn, Germany). Owing to the lack of selection markers in this plasmid and the presence of a SV40 promoter, which expresses genes optimally in cells expressing the large T antigen, the 3.2 kb bovine NAT cDNA (bNAT) was initially subcloned into the EcoR1 site of the pIND vector (Invitrogen, De Schelp, The Netherlands). As only one restriction enzyme was used for subcloning into the pIND plasmid, the bNAT cDNA was present in different clones, in both sense and antisense orientations. The latter plasmid has suitable restriction enzyme sites for subcloning the bNAT cDNA into the KpnI/Xho sites of the I MIBG uptake M Boyd et al pREP9 episomal expression vector (Invitrogen), which was chosen for this gene transfer study. Restriction mapping of the different clones identified pREP9/NAT recombinant plasmids with the insert in both orientations (results not shown). Subcloning into the pIND and pREP9 plasmids was carried out by standard methods. Plasmid purifications were carried out using Plasmid Maxi Kit (Qiagen, Germany).
Target cells
The transgene host was a radiation-resistant human glioma cell line (UVW). The UVW cell line was chosen for this study in preference to other available glioma cell lines because of its capacity for spheroid formation in stirrer culture. The UVW cell line was maintained in Eagle's minimum essential medium (MEM) (Life Technologies, Paisley, UK) with 10% (v/v) fetal bovine serum, penicillin/streptomycin (100 U/ml), fungizone (2 g/ml) and glutamine (200 mm). The cells were incubated at 37°C in an atmosphere of 5% CO 2 .
UVW transfection
Fifty per cent confluent UVW monolayers seeded at 5 × 10 3 cells per well in six-well plates 48 h before use, were transfected with 3 g plasmid DNA (pREP9/bNAT in both orientations) using DOTAP Liposomal Transfection Reagent (Boehringer Mannheim, Mannheim, Germany) in accordance with the manufacturer's instructions. After 24 h, geneticin G-418 sulphate (Life Technologies) was added at a concentration of 0.5 mg/ml to select for transfected cells. The transfectants were maintained as described for UVW cells with the addition of geneticin at each passage. Transfectants were assessed monthly for mycoplasma infection, which was consistently absent, and for MIBG uptake (persistent expression of the bNAT gene).
MIBG uptake studies UVW/pNAT+ and UVW/pNAT− cells were seeded in six-well plates at an initial density of 0.5 × 10 5 cells per well and cultured for 48 h. MIBG incorporation was measured by incubating the cells for 2 h with 7 kBq of 131 I MIBG of specific activity 45-65 MBq/mg, (Dupont Radiopharmaceuticals, Hertfordshire, UK). Nonspecific uptake was measured in the presence of 1.5 mm desmethylimipramine (DMI) (Sigma-Aldrich, Dorset, UK). After incubation, medium was removed, the cells were washed with PBS and radioactivity was extracted using two aliquots of 10% (w/v) trichloroacetic acid. The activities of the extracts were then measured in a gamma-well counter. Uptake was expressed as c.p.m. per 10 5 cells.
Clonogenic assays UVW/pNAT+ and UVW/pNAT− cells were seeded in 25 cm 2 flasks at 0.5 × 10 5 cells per flask. After 2 days, medium was removed and replaced with fresh medium alone or medium containing 131 I MIBG at 100, 500, 750 or 1000 kBq/ml. After incubation for 2 h, medium was removed and the cells were washed three times with PBS. Cells were then trypsinized and counted. For each radioactivity concentration, three 35 mm Petri dishes (Nunc Plastics, Oslo, Denmark) were seeded with 1 × 10 3 cells. The cultures were then incubated at 37°C. After 10-14 days, medium was removed and the colonies were fixed and stained with Carbol Fuchsin (R A Lamb, Middlesex, UK). Colonies of more than 50 cells were counted using an automated colony counter (Synoptics, Cambridge, UK).
Spheroid experiments
To investigate the contribution of ␤-particle cross-fire to cell kill, a three-dimensional multicellular spheroid model was used. Spheroids were grown by continuously stirring 3 × 10 6 UVW/pNAT+ or UVW/pNAT− cells in Techne stirrer flasks (Techne, Cambridge, UK). Spheroids of approximately 250-300 m diameter were obtained after 4-5 days growth. Aliquots were transferred to 20 ml universal containers and suspended in 1 ml of MEM containing the appropriate activity of 131 I MIBG. After incubation for 2 h at 37°C, the medium was removed and the spheroids washed three times with PBS. Two types of spheroid experiment were undertaken with different endpoints -spheroid clonogenic assay and spheroid growth delay assay.
Spheroid clonogenic assay: Fresh culture medium was added to the washed spheroids which were then incubated at 37°C for 24 h. To prevent clumping, the spheroids were shaken continuously. They were then incubated for 10 min at 37°C with PBS containing 0.25% (v/v) trypsin and 1 mm EDTA and mechanically disaggregated using a syringe. Microscopic examination confirmed that the cell preparations were free from clumps. Cells were then counted and seeded into 60 mm Petri dishes for clonogenic assay, as described above.
Spheroid growth delay: Spheroids were transferred to Petri dishes and individually transferred into agar-coated wells containing 1 ml of MEM medium. One 24-well plate was used per treatment. The spheroids were incubated at 37°C in a 5% CO 2 atmosphere. Growth of the spheroids was monitored over 2-3 weeks by measurement of their cross-sectional area, using a semiautomated image analysis system coupled via a television camera to an inverted optical microscope. From these measurements, the median volume of the spheroids was calculated to allow the construction of spheroid regrowth curves.
